- Home
- ARGX vs ZBH Comparison
ARGX vs ZBH Comparison
Compare ARGX & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- ZBH
- Stock Information
- Founded
- ARGX 2008
- ZBH 1927
- Country
- ARGX Netherlands
- ZBH United States
- Employees
- ARGX N/A
- ZBH N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- ZBH Industrial Specialties
- Sector
- ARGX Health Care
- ZBH Health Care
- Exchange
- ARGX Nasdaq
- ZBH Nasdaq
- Market Cap
- ARGX 40.4B
- ZBH 22.4B
- IPO Year
- ARGX 2017
- ZBH N/A
- Fundamental
- Price
- ARGX $590.06
- ZBH $112.72
- Analyst Decision
- ARGX Strong Buy
- ZBH Buy
- Analyst Count
- ARGX 20
- ZBH 22
- Target Price
- ARGX $682.00
- ZBH $124.15
- AVG Volume (30 Days)
- ARGX 373.1K
- ZBH 1.7M
- Earning Date
- ARGX 05-08-2025
- ZBH 05-01-2025
- Dividend Yield
- ARGX N/A
- ZBH 0.85%
- EPS Growth
- ARGX N/A
- ZBH N/A
- EPS
- ARGX 12.78
- ZBH 4.43
- Revenue
- ARGX $2,248,205,000.00
- ZBH $7,678,600,000.00
- Revenue This Year
- ARGX $57.86
- ZBH $3.68
- Revenue Next Year
- ARGX $31.90
- ZBH $4.53
- P/E Ratio
- ARGX $43.50
- ZBH $25.43
- Revenue Growth
- ARGX 77.22
- ZBH 3.85
- 52 Week Low
- ARGX $352.77
- ZBH $97.69
- 52 Week High
- ARGX $678.21
- ZBH $130.89
- Technical
- Relative Strength Index (RSI)
- ARGX 44.86
- ZBH 60.25
- Support Level
- ARGX $565.00
- ZBH $110.85
- Resistance Level
- ARGX $598.06
- ZBH $113.64
- Average True Range (ATR)
- ARGX 14.20
- ZBH 2.19
- MACD
- ARGX -0.77
- ZBH 0.05
- Stochastic Oscillator
- ARGX 40.42
- ZBH 68.00
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.